The FDA Moves to Restrict Sale of Bayer's Essure® Birth Control Device as Sales Continue to Decline

Essure on Facebook

The FDA is taking this step after becoming aware that some women were not being adequately informed of Essure’s risks before getting the device implanted

The FDA doesn’t provide any remedy whatsoever for the person who was harmed… The only person who can help them is an attorney experienced in dealing with potentially harmful medical devices.”

— Martin Schmidt

SAN DIEGO, CALLIFORNIA, UNITED STATES, June 21, 2018 /EINPresswire.com/ — Sales of Bayer’s permanent birth control device Essure® are down 70 percent in the United States, according to the U.S. Food and Drug Administration (FDA). Those sales could continue to drop after the agency announced it would restrict sales of the device in the U.S.

The FDA announced in early April it would begin restricting sales of Essure® in the U.S. because women were still getting the potentially dangerous device without being fully informed of its risks.

“The FDA is aware that some women have received the Essure® device without being adequately informed of Essure’s risks,” reads the FDA’s announcement on its website. The regulatory agency said it would restrict sales of Essure® to only those healthcare providers who agreed to review and sign a patient-doctor checklist before implanting the device.

The FDA required Bayer, the maker of Essure®, to provide a patient-doctor checklist in 2016 after thousands of complaints poured into the FDA’s adverse events database regarding potential risks of the contraceptive device.

Risks of Essure® include severe abdominal pain, migration of the device, device breakage, perforation of organs by the device, and unintended pregnancy, among dozens of others.

On April 9, the FDA said only those healthcare providers who provide and sign the checklist will be able to sell Essure®.

“The FDA is taking this step after becoming aware that some women were not being adequately informed of Essure’s risks before getting the device implanted, despite previous significant efforts to educate patients and doctors about the risks associated with this device,” reads a press release issued by the FDA.

These “significant efforts” included implementing the patient-doctor checklist and adding a Black Box Warning—the FDA’s strongest warning short of a device recall—in 2016. The agency also required Bayer conduct post-market studies on Essure® to ensure the device was indeed as safe and effective as the manufacturer claimed.

According to the FDA, there has been about a 70 percent decline in sales of Essure® in the U.S. since the agency ordered the post-market studies and added the black box warning and patient-doctor checklist more than two years ago.

Will these sales decline even further when a new documentary about the unchecked power of the medical device industry and featuring Essure is available for millions of Americans to view this summer?

Attorney Martin Schmidt filed one of the first Essure® lawsuit in the state of California in 2015, spearheading the fight to get Bayer’s permanent birth control device off the market. Schmidt says filing an Essure® lawsuit is the only way to hold Bayer accountable and to help women exposed to Essure’s risks seek justice.

“The FDA doesn’t provide any remedy whatsoever for the person who was harmed by a drug or medical device that failed. The only person who can really help them is a plaintiff attorney who is experienced in dealing with potentially harmful medical devices and drugs,” says Schmidt.

Call Schmidt National Law Group toll free at 800-631-5656 or visit National Injury Advocates on the web.

About Schmidt National Law Group: In his 30 years as a trial attorney, Martin Schmidt has represented many victims of defective drugs as well as those injured by defective products and personal injury accidents. Martin Schmidt has been recognized as a leading personal injury attorney, having been chosen as one of the "Top 100 Trial Lawyers" for the state. Schmidt National Law Group is a personal injury firm located in San Diego, California, and its attorneys represent victims of all types of injuries.

Martin Schmidt
Schmidt National Law Group
800-631-5656
email us here


Source: EIN Presswire

Are PTSD Suicides Connected to Psychiatric Drug Treatment?

The Hidden Enemy: Inside Psychiatry's Covert Agenda

The Hidden Enemy: Inside Psychiatry’s Covert Agenda

CCHR Florida

CCHR Florida

CCHR Florida

CCHR Florida

Eighty percent of war veterans treated for PTSD are given psychiatric drugs and government agencies spend $9 billion a year on their mental health budgets.

Suicidal ideation is a black-box warning on psychiatric drugs given to our veterans. These drugs have never been shown to reduce risk or incidence of suicide. Shouldn’t this information be made known?”

— Diane Stein, President of Citizens Commission on Human Rights of Florida

CLEARWATER, FLORIDA, UNITED STATES, June 21, 2018 /EINPresswire.com/ — June has been designated PTSD Awareness Month by the National Center for Post-traumatic Stress Disorder (PTSD). The purpose of this designation is to increase awareness of “a mental health problem that may develop after a person has been exposed to … traumatic events.”

Events that may prompt being labeled with PTSD include threats to one’s life such as assault, wartime combat, terrorism, natural or human-made disasters. The listed symptoms include “distressing dreams, persistent thoughts and recurring flashbacks about the traumatic event or events, numbing or avoidance of memories of the trauma and triggered emotional responses.” [1]

But according to some there is a dark side to the PTSD Awareness campaign, that centers on the issue of treatments, and whether some of these are in fact causing more harm than good.

Today, some 80% of veterans labeled with PTSD receive psychotropic drugs; 89% of these are given antidepressants, with 34% treated with antipsychotics – drugs so dangerous many of them are labeled with the strictest warnings issued by the FDA. All told, the Department of Defense and the Veterans Administration collectively spend $9 billion a year on their mental health budgets.[2]

Simultaneously with the drugging of our veterans, twenty American armed force veterans are committing suicide every day. In 2014, more than 7,400 took their own lives. And although military veterans make up only 9 percent of the population, they account for 18 percent of all suicides.[3]

In the past “PTSD” was called “shell shock” or “battle fatigue.” But psychiatric diagnosis has redefined the condition as a “mental disorder”, thus making the sufferers eligible for billable psychiatric drug treatment.

Concurrently, the epidemic of suicides among U.S. military has increased in parallel along with the diagnoses of PTSD and the prescribing of psychiatric drugs, many of which are known to cause suicidal side effects.

The increase of dosing U.S. military veterans with psychiatric drugs is unprecedented. In less than a decade, from 2005 to 2011, The US Department of Defense increased its prescriptions of these pharmaceuticals almost seven times. This equates to thirty times faster than the civilian population. Currently, one in six American service members are on at least one psychiatric drug.

Former US Army Sergeant Joel Kort had this to say about the PTSD-type treatment he received as a soldier, “I didn’t see the emergence of psychiatry in the Army until I suffered my own injury, and then it was like a flood. It was a flood of doctors and it was a flood of meds…. I know that I’ve been on Ambien, Seroquel, Paxil—that was one of the big ones. A very dangerous drug…called Abilify. It kind of puts whatever meds you’re on, on steroids.” [3]

Since 1945, military personnel have been subject to aggressive psychiatric experimentation. Over 73 years ago, psychiatrist and Brigadier General J.R. Rees observed: “The army and the other fighting services form rather unique experimental groups since they are complete communities and it is possible to arrange experiments in a way that would be very difficult in civilian life.”

American soldiers in World War II were subjected to psychiatric experimentation when electroshock, insulin shock and varieties of mind-altering drugs were tried out on psychologically wounded soldiers.

Today the mental “diagnosis” is carried out by a licensed psychiatrist for “a preponderance of the evidence” since there are no medical tests for the condition. The criteria and naming of the disorder is decided by committee vote for inclusion in the Diagnostic and Statistical Manual of Mental Disorders, so as to make it an insurable and billable condition.

“In Florida alone, two of our veterans commit suicide every day”, said Diane Stein, President of Citizens Commission on Human Rights of Florida. “Suicidal ideation is a black-box warning on the labels of psychiatric medications given for PTSD to military vets. These medications have never been shown to reduce risk or incidence of suicide – on the contrary. Shouldn’t this information be part of “PTSD Awareness Month?”.[4]

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world. In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health.’” For more information visit, www.cchrflorida.org

Sources:

[1] https://www.awarenessdays.com/us/awareness-days-calendar/national-ptsd-awareness-day-in-the-usa-2018/

[2] https://www.cchrint.org/issues/the-hidden-enemy/

[3] https://www.militarytimes.com/veterans/2016/07/07/new-va-study-finds-20-veterans-commit-suicide-each-day/

[4] https://www.mentalhealth.va.gov/docs/data-sheets/Suicide-Data-Sheet-Florida.pdf

Diane Stein
Citizens Commission on Human Rights of Florida
(727) 422-8820
email us here

Colonel Bart Billings, Psychologist—Help our Veterans, Don’t Label & Drug Them


Source: EIN Presswire

From ADHD to Cocaine: A Wake-Up Call for Parents

Over a million children under the age of six are currently on psychiatric drugs in America

Over a million children under the age of six are currently on psychiatric drugs in America

The headquarters for CCHR Florida are located in downtown Clearwater

The headquarters for CCHR Florida are located in downtown Clearwater

CCHR Florida

Mr. Jason Good, speaks of his personal experience being labeled with ADHD as a child and how this led to a narcotics addiction at the age of 15.

Parents are vulnerable because they want the best for their children. Lacking information on the possible side effects of these drugs, they may too easily give permission and regret it much later.”

— Diane Stein, President CCHR Florida

CLEARWATER, FLORIDA, UNITED STATES, June 21, 2018 /EINPresswire.com/ — Prompted by new information on the use of psychotropic drugs to treat childhood difficulties in school, the Citizens Commission on Human Rights (CCHR) regularly hosts an educational talk for parents and concerned individuals on psychostimulants and the potential for drug addiction.

Today in the United States approximately 1.8 million youths aged 12 to 17 are using prescription psychotropic drugs, largely to treat difficulties with study.

The psychostimulant, methylphenidate is a Schedule II drug, which means the U.S. Drug Enforcement Administration (DEA) classifies it as having a high potential for abuse. Today it is prescribed largely to children and adolescents for “Attention Deficit Hyperactivity Disorder” (ADHD).

At the same time, the DEA warns that methylphenidate produces many of the same effects as cocaine. Psychotic episodes and severe psychological addiction have all been associated with methylphenidate abuse. [1]

This labeling represents a billing code that has come under increasing criticism for labeling normal childhood as a “mental disease”.

The side effects for Ritalin (methylphenidate hcl), used widely for ADHD, include nervousness, agitation, and anxiety as the top 3 listed effects, as well as psychosis.[2]

“Parents are vulnerable because they want the best for their children,” said Diane Stein, President CCHR Florida. “Lacking information on the possible side effects of these drugs, they may too easily give permission and regret it much later.”

During this talk, guest speaker and public executive of a successful drug rehabilitation center, Mr. Jason Good, speaks of his personal experience being labeled with ADHD as a child which came with one psychotropic drug after another from his doctors. Those in attendance hear the true story of how a Ritalin prescription handed to a young boy caused illegal street drug use and a narcotics addiction at the age of 15 and what Mr. Good thinks can be done to protect children in today's society.

For more information or to find out when the next educational briefing will be held, please call CCHR at 727-442-8820 or visit the center at 109 N. Fort Harrison Ave, Clearwater, Florida.

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world. In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health.’” For more information visit, www.cchrflorida.org

Sources:

[1] https://www.prnewswire.com/news-releases/cchr-alerts-parents-about-new-federal-statistics-showing-rates-of-youth-overdose-deaths-on-adhd-stimulants-and-benzodiazepines-are-greater-than-on-cocaine-300507566.html

[2] https://www.rxlist.com/ritalin-side-effects-drug-center.htm

Diane Stein
Citizens Commission on Human Rights of Florida
(727) 422-8820
email us here

CCHR: What We Believe


Source: EIN Presswire

Dr. Susana Trujillo Introduces: Taking Fucoidan (Mozuku, Mekabu & Fucus) Can Support Your Immunity

Best Fucoidan

Fucoidan 3-Plus

Best Types of Fucoidan

Buying the most effective Fucoidan and other dietary supplements is not an easy task.

NEW YORK, NEW YORK, UNITED STATES, June 21, 2018 /EINPresswire.com/ — Vitamins, minerals, micronutrients, polysaccharides, enzymes and probiotics are required for the normal functions of our body, and they work in synergy. All nutrients participate in complex metabolic processes in our body and interact with other nutrients either by enhancing or opposing their action. Their optimal interaction and cellular balance is the basis of health.

The most effective dietary supplementation can be achieved by combining specific and properly selected ingredient combinations. Consumption of certain ingredients has been associated with prevention of the development and progression of cancer. For example, Fucoidan, a natural sulfated polysaccharide, is extracted from various species of brown seaweed such as Mozuku, Mekabu (wakame) and Fucus. Fucoidan has shown to trigger apoptosis, inhibit inhibits the formation of new vessels by which tumor cells receive their oxygen and required nutrients (Angiogenesis) and it enhances the immune system.

Fucoidan along with other ingredient blends or combinations can:

· Help produce energy in the body’s cells.

· Help to maintain balanced cellular metabolism.

· Improve the body’s functions.

· May help to inhibit the invasion of cancer cells.

· Provide the balance needed to function better at a cellular level.

Nutrient synergy makes it possible to affect multiple biological targets at once. Studies have shown that such a synergy combination can simultaneously affect key mechanisms of cancer, improve functions of many organs, as well as having many other benefits.

It is important to remember that no single nutrient works alone in the body and that any single nutrient, or their random combinations, may result in biochemical imbalances in our body. Therefore, a person needs to be selective when consuming these natural ingredients.

Now, let’s look at the mechanism of cancer metastasis to get an idea of how these nutrients (Fucoidan, micronutrients, etc.) can support the body.

The Mechanism of Cancer Metastasis

Cancer cells use various mechanisms to grow, spread and ultimately overpower the body:

1. Cancer cell invasion and metastasis. The most critical mechanism is the ability of cancer cells to digest the connective tissue surrounding them and thereby pave the way for invasive growth and metastasis to other organs.

2. Cancer cell multiplication and tumor growth. A characteristic feature of cancer cells is a change in the biological ‘software’ in the cell core (nucleus) that renders them immortal. This explains why cancer cells multiply indefinitely – thereby gradually increasing tumor size and ultimately overwhelming the body.

3. Formation of new blood vessels that feed the tumor (Angiogenesis). If the tumor surpasses a certain size, normally 1/20 of an inch, the tumor cells can no longer be nourished from within. Therefore, growing tumors induce the formation of new blood vessels that supply oxygen and nutrients for further growth. This formation of new blood vessels is called ‘angiogenesis’. The blocking of angiogenesis has become an important target of international anti-cancer research.

4. Inducing the natural death of cancer cells (Apoptosis). We already know cancer cells never die. The immortality of cancer cells is due to a genetic ‘switch’ in the cell core. Correcting this abnormality and reversing this ‘switch’ induces natural cell death. This is a precondition for stopping the continuous multiplication of cancer cells and ultimately leading to the shrinkage and disappearance of tumors. Effectively blocking even one of these mechanisms can be sufficient to control cancer.

Ingredients that Best Work in Synergy for Optimal Health

Ingredients that Inhibit the Invasion of Cancer and Tumor Growth

Dietary supplements include macronutrients, vitamins, and minerals that are essential to human health as well as a wide variety of nonessential nutrients, such as certain phytochemicals, polysaccharides and herbs.

Ingredients that best work in synergy for optimal health:

• nutrient-rich polysaccharides (Fucoidan)

Fucoidan has shown to induce cell death within tumor cells and to increase the survival rate by suppression of metastasis and angiogenesis. The goal of cancer treatment is suppression of tumor cells ideally with minimal damage to healthy tissues. Because of the side-effects of many current treatments, the use of natural substances that cause no harm to the human body is important. A number of in vitro and in vivo studies have indicated that Fucoidan contains strong anti-cancer properties. Since Fucoidan also possesses immunomodulatory effects, it may have protective effects against development of side effects caused by the chemotherapy or radiation therapy.

A blend of three different Fucoidan extracts (Fucoidan from Mozuku, Mekabu (wakame) and Fucus) in a synergistic blend offer greater health benefits due to the wide variation of fucoidan structures, fucoidan content, sulfate content, monosaccharide constituents and molecular weight. Attention to these factors is important to be able to obtain the positive and effective results for the alternative treatment or prevention of cancer.

The most remarkable Fucoidan extracts are:

o Fucoidan Mekabu (Undaria pinnatifida) studies:

§ Fatigue: Clinical studies in Japan have noted that ingestion of 4.05 g per day of fucoidan (Cladosiphon okamuranus) reduced “fatigue” caused by common chemotherapeutic agents compared to those not taking fucoidan. Patients taking Fucoidan were able to tolerate more rounds of chemotherapy.

o Fucoidan Mozuku (Cladosiphon okamuranus) studies:

§ Breast Cancer: Fucoidan from Mozuku (Cladosiphon okamuranus) could be useful as an alterntive oral therapy during or after chemotherapy or radiation therapy. Several studies, using in vitro models, have noted shown potential synergies with chemotherapy.

§ Liver Diseases: Fucoidan has also shown to benefit non-alcoholic liver disease caused by a pathogen. Hepatitis C is a viral infection that can lead to cirrhosis of the liver and hepatocellular carcinoma. Currently there is no available vaccine and the response rates to conventional treatments are less than ideal, however recent research suggests that there is significant potential for fucoidan in this area.

o Fucoidan Fucus (Fucus vesiculosus) studies:

§ Gastrointestinal problems caused by chemotherapy: Fucoidan can also be used as an agent to reduce the side effects of side effects from gastrointestinal problems during chemotherapy.

As you can see, there’s really nothing like Fucoidan 3-Plus on the market today.

By Dr. Susana Trujillo

Dr. Susana Trujillo
Dr. Susana Trujillo
2134788815
email us here

Fucoidan Health Benefits


Source: EIN Presswire

MAFAZO Is Now Ignyte Assurance Platform

Decision Comes After Company Takes a New Direction as It Orients Itself Primarily as a Risk Management Product Company.

Our new name emphasizes our commitment to our vision and reminds us to deliver on our promises through automation.”

— Max Aulakh

DAYTON, OHIO, U.S, June 21, 2018 /EINPresswire.com/ — Ignyte Assurance Platform
Ehron Ostendorf
(937) 361-3198
ehron@mafazo.com

Dayton, Ohio: MAFAZO LLC changes name to Ignyte Assurance Platform (Ignyte). MAFAZO rebranded to Ignyte Assurance Platform (IAP) as the company refocuses from being a services company to providing industries’ first cyber assurance product platform.

“Our new name emphasizes our powerful expertise in cybersecurity engineering and our approach to building long-term service engagements as a trusted partner,” said Max Aulakh, President of Ignyte. “It articulates our commitment to our vision and reminds us to deliver on our promises through automation.”

The name change is effective immediately. The company chose “Ignyte Assurance Platform” after working closely with a Chief Marketing Officer and several key customers to develop its name. Ignyte is dedicated to providing its clients with an advanced cyber security assurance product and the name change reflects this transition.

“We had multiple, fantastic discussions with CEO of Ignyte as we tethered together ideas on how to help with existing Federal Regulations for researchers and clinicians that the ACMG supports,” said Dr. Bruce Bowdish.“Ignyte pushed the organizational changes needed to comply with fast-changing cybersecurity missions while likewise providing the underlying ‘engine’ needed to power efficient data management and reporting capabilities.”

Since the inception of the company, MAFAZO has been delivering high-end services engagements such as cyber systems integration, custom cyber product development, assessments and penetration testing for prestigious firms such as Department of Defense, Dell and many others.

The transition allows the company to regain its strength and focus on its highest and best use in providing an advanced cybersecurity software assurance product to its existing customers while gaining new customers.

This decision
• Reflects the company’s new direction
• Announces the change of focus from services to a product
• Revisions and redefines the company’s purpose

About the Company: Ignyte Assurance Platform is a leader in collaborative security and integrated GRC solutions for global corporations. Max Aulakh founded Ignyte Assurance Platform in January 2012 as “MAFAZO LLC.” MAFAZO established a strategic contract relationship with the U.S Department of Defense Agencies at a very early stage of the company. After that, the company rocketed forward as Ignyte Assurance Platform.

Max began expanding the Ignyte team, which is comprised of multidisciplinary professionals from diverse backgrounds. Ignyte later performed cyber service engagements for global organizations and many are transitioning to the Ignyte Platform.

Today, Ignyte orients itself primarily as a risk management product company. Ignyte provides military grade software that makes compliance effortless, which assists with data collection, analysis, and helps streamline processes across multiple security frameworks at once. To find out all that we do, follow the link Ignyte Assurance Platform’s website.

Ehron Ostendorf
Ignyte Assurance Platform
(937) 361-3198
email us here


Source: EIN Presswire

Analytics 4 Life Selects Massey Consulting as Technology Partner in ERP Implementation

Digital health leader, Analytics 4 Life, selects Massey Consulting as its technology partner to successfully implement a cloud-based ERP software.

RALEIGH, NC, NC, UNITED STATES, June 21, 2018 /EINPresswire.com/ — Massey Consulting, a leading accounting software technology firm announced that they have been selected by digital health leader, Analytics 4 Life, to successfully implement cloud-based accounting software, Sage Intacct.

Analytics 4 Life is dedicated to transforming healthcare with a proprietary method of cardiac imaging that employs artificial intelligence, cloud computing, and digital technologies. Analytics 4 Life is headquartered in Toronto with an office in Research Triangle Park, NC.

A change in the company’s financial accounting system was necessitated by their rapidly changing business needs. With its multiple locations and fast-paced growth, Analytics 4 Life was pushing the limits of its on-premise accounting system.

“Our recent announcement of expanding our clinical program to China made it very apparent that we needed an accounting solution that could easily scale with our growing business,” said Nicholas Leb, Vice President and CFO of Analytics 4 Life. “Analytics 4 Life requires robust reporting, multi-currency and multi-entity capabilities, and the ability to consolidate all financials, all of which Sage Intacct provides.”

Massey Consulting will work with Analytics 4 Life from the discovery process through the implementation of Sage Intacct to transition its financial accounting and reporting system to the cloud. “Analytics 4 Life will greatly benefit from its move to a cloud-based solution,” explained Philip Massey, CPA and President of Massey Consulting. “An automated, customizable financial management system like Sage Intacct will give Analytics 4 Life the flexible reporting capabilities it needs.”

About Analytics 4 Life

Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new form of medical imaging. With an initial focus on coronary artery disease, Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac imaging technology aimed at improving existing care pathways. Analytics 4 Life is based in Toronto with U.S. headquarters in Research Triangle Park, NC. For more information, visit www.analytics4life.com.

About Massey Consulting

Massey Consulting, located in Raleigh, NC, is a full-service consulting firm that specializes in various implementations and integrations of accounting software. Massey Consulting often integrates front-end operations management systems with back-end financial software, like Sage Intacct or Dynamics GP, to create a seamless business management tool. The Massey team is comprised of technology consultants that have experience as accountants, controllers, and information systems experts. Recognized as a Microsoft Gold Partner and Sage Intacct Premier Partner since 2013, Massey Consulting serves over 100 clients across the United States, Canada, and Australia. To learn more, visit www.masseyconsulting.net

Jelena Subasic
Massey Consulting
919-508-6063
email us here


Source: EIN Presswire

Pet Daycare and Lodging Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2025

WiseGuyReports.com adds “Pet Daycare and Lodging Market 2018 Global Analysis, Growth, Opportunities Research Report Forecasting to 2025”reports to its database.

PUNE, INDIA, June 21, 2018 /EINPresswire.com/ — Pet Daycare and Lodging Market:

Executive Summary

This report studies the global Pet Daycare and Lodging market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Pet Daycare and Lodging market by companies, region, type and end-use industry.

This report focuses on the global top players, covered

Best Friends Pet Care
Camp Bow Wow
Dogtopia
PetSmart Home Office
Preppy Pet
Barkefellers
Camp Run-A-Mutt
Central Bark Doggy Daycare
Country Comfort Kennels
Country Paws Boarding
The Dog Stop
Paradise 4 Paws
Pet Station Kennels & Cattery
Puss 'n' Boots Boarding Cattery
Royvon
Urban Tails Pet Resort
Market segment by Regions/Countries, this report covers

United States
Europe
China
Japan
Southeast Asia
India
Market segment by Type, the product can be split into

Dog Daycare and Lodging
Cat Daycare and Lodging
Combined Daycare and Lodging
Market segment by Application, Pet Daycare and Lodging can be split into

Dog Care
Cat Care
Fish Care
Bird Care
Reptile Care
Small Pet Care

Request Sample Report @ https://www.wiseguyreports.com/sample-request/3163769-global-pet-daycare-and-lodging-market-size-status-and-forecast-2025

The study objectives of this report are:

To study and forecast the market size of Pet Daycare and Lodging in global market.
To analyze the global key players, SWOT analysis, value and global market share for top players.
To define, describe and forecast the market by type, end use and region.
To analyze and compare the market status and forecast between China and major regions, namely, United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Pet Daycare and Lodging are as follows:

History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders
Pet Daycare and Lodging Manufacturers
Pet Daycare and Lodging Distributors/Traders/Wholesalers
Pet Daycare and Lodging Subcomponent Manufacturers
Industry Association
Downstream Vendors
Available Customizations

With the given market data, We offers customizations according to the company's specific needs. The following customization options are available for the report:

Regional and country-level analysis of the Pet Daycare and Lodging market, by end-use.

Detailed analysis and profiles of additional market players.

Table of Content:

Global Pet Daycare and Lodging Market Size, Status and Forecast 2025
1 Industry Overview of Pet Daycare and Lodging

2 Global Pet Daycare and Lodging Competition Analysis by Players

3 Company (Top Players) Profiles

4 Global Pet Daycare and Lodging Market Size by Type and Application (2013-2018)

5 United States Pet Daycare and Lodging Development Status and Outlook

6 Europe Pet Daycare and Lodging Development Status and Outlook

7 China Pet Daycare and Lodging Development Status and Outlook

8 Japan Pet Daycare and Lodging Development Status and Outlook

9 Southeast Asia Pet Daycare and Lodging Development Status and Outlook

10 India Pet Daycare and Lodging Development Status and Outlook

11 Market Forecast by Regions, Type and Application (2018-2025)

12 Pet Daycare and Lodging Market Dynamics

13 Market Effect Factors Analysis

14 Research Finding/Conclusion

15 Appendix

Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/3163769-global-pet-daycare-and-lodging-market-size-status-and-forecast-2025

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Public urged to take online screener as preventable causes of liver disease are on the rise

To mark Love Your Liver Week (18 to 24 June), the UK public are being urged by the British Liver Trust to take an online liver health screening tool.

Liver disease affects millions of people in the UK – and the numbers diagnosed have been increasing at an alarming rate.”

— Judi Rhys, Chief Executive at British Liver Trust

BOURNEMOUTH, SURREY, UK, June 21, 2018 /EINPresswire.com/ — To mark Love Your Liver Week (18 to 24 June), the UK public are being urged by the British Liver Trust to take an online screening tool so that they can find out if they are at risk of liver disease. Deaths from liver disease have increased by 400% since the 1970s and it is one of the leading causes of premature death in the UK.

Liver disease develops silently with no obvious symptoms in the early stages yet it is almost entirely preventable with the major risk factors: alcohol, obesity and viral hepatitis, accounting for up to 90% of cases.

The Love Your Liver awareness campaign, promoted by the British Liver Trust, aims to reach the one in five people in the UK who may have the early stages of liver disease, but are unaware of it. The screener assesses the potential for liver damage against the three main risk factors of the disease.

Liver disease is one of the leading causes of premature death in England and is responsible for more than 1 in 10 deaths of people in their 40s.

Judi Rhys, Chief Executive, British Liver Trust said, “Liver disease affects millions of people in the UK – and the numbers diagnosed have been increasing at an alarming rate. It is a silent killer and people often don’t realise they have a problem until it is too late. Although the liver is remarkably resilient, if left too late the damage is often irreversible.

“Helping people understand how to reduce their risk of liver damage is vital to address the increase in deaths from liver disease,” continues Judi. “I would urge everyone to take our online screener on our website to see if they are at risk.”

The British Liver Trust’s Love Your Liver campaign focuses on three simple steps to Love Your Liver back to health:
• Drink within recommended limits and have three consecutive alcohol-free days every week
• Cut down on sugar, carbohydrates and fat and take more exercise
• Know the risk factors for viral hepatitis and get tested or vaccinated if at risk

Finding out your risk of liver disease only takes a few minutes. It could be the most important thing you do today. Take the British Liver Trust’s screener here: https://www.britishlivertrust.org.uk/our-work/love-your-liver/love-liver-health-screener/

Natasha British Liver Trust
British Liver Trust
07922 645009
email us here


Source: EIN Presswire

North America's Cardiovascular Drugs Market To Shrink 5% 2013-21

Cardiovascular Drugs Market Growth Rates By Region

Cardiovascular Drugs Market Growth Rates By Region

LONDON, GREATER LONDON , UK, June 21, 2018 /EINPresswire.com/ — The North American market for drugs to treat heart disease fell by 2.9% year on year from 2013 to 2017 and although growth has picked up to 1.7% that still means that by 2021 it will be 5% smaller than it was in 2013. Up to 2017 it remained North America's largest market for drugs but by 2021 it will be overtaken by the markets for treating metabolic disorders such as diabetes and thyroidism. Drugs for treating arthritis, osteoporosis and other musculoskeletal conditions will also be neck and neck with the cardiovascular drugs in the North American market by 2021.

The cardiovascular drugs category covers drugs used to treat conditions that include heart attack or failure, strokes, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and angiotensin II receptor antagonists, and hypolipidemic drugs such as fibric acid derivatives and bile acid binding resins.
In a region such as North America, which largely consists of the highly developed countries the USA and Canada, but also includes Mexico, drug spend is related to disease incidence and the development of new high-priced patented drugs as well as to population growth or GDP per capita. While heart attacks and strokes are still the leading cause of death in the USA, other conditions such as diabetes have increased in significance due to obesity and other lifestyle factors. Population aging and the availability of new treatments for arthritis and osteoporosis are boosting the market for musculoskeletal drugs.
The market for cardiovascular drugs is performing less well than any other major segment globally as well as in North America, having fallen year on year by 2% to 2017 and set to grow by only 2.2% annually to 2021. In Western Europe it is declining year on year throughout the eight-year period. Even in Asia Pacific it is achieving only a little over 5% a year, compared with over 8% for the pharma market as a whole in that region.

The global cardiovascular drugs market is fragmented – nearly 70% goes to players outside the top ten. The USA's Merck and Co with a nearly 8% market share, is the market leader, followed by French pharma company Sanofi with around 5%.

Where To Learn More
Read the Pharmaceutical Drugs Global Market Report 2018 from The Business Research Company for information on the following:
Markets covered: Markets for pharmaceuticals cardiovascular drugs, central nervous system drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorder drugs, musculoskeletal drugs, oncology drugs, ophthalmology drugs, respiratory drugs
Pharmaceutical Companies Covered: Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson, GlaxoSmithKline Plc., Bayer AG, Teva Pharmaceuticals, Merck & Co.
Regions: North America, Asia Pacific, Western Europe, South America, Eastern Europe, Middle East, Africa.
Countries: USA, China, Japan, Germany, Brazil, France, Italy, UK, Australia, India, Spain, Russia.
Time Series: Five years historic (2013-17) and forecast (2017-21).
Data: Pharmaceutical market size and growth for 7 regions and 12 countries; pharmaceutical global regional and country market size and growth segmented by therapeutic area; market trends & strategies, market size by sub segment historic and forecast growth rate, by sub segment, competitive landscape, profiles of leading competitors, key mergers and acquisitions by each therapeutic segment, global, regional and country pharmaceutical per capita consumption and market size as a percentage of GDP 2013-21; leading competitors' financial performance 2013-21; pharmaceutical drugs market comparison with industry metrics.
Data Segmentations: Pharmaceutical drugs global market, global pharmaceutical drugs market by therapeutic area segments and sub segments; pharmaceutical drugs market by region and country and by therapeutic area segments; branded versus generic drugs markets by country; competitor drug sales and market shares by therapeutic area; global healthcare market historic and forecast size and growth; healthcare market regional and country size and growth; healthcare market competitive landscape.
Other Information: PESTEL analysis, drivers and restraints, customer and operational insights, pharmaceutical drugs market by country covering opportunities, industrial gas associations, investment and expansion plans, corporate tax structure and competitive landscape.
Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes. Sources include primary as well as extensive secondary research.
Interested to know more? Here is a list of reports similar to “Pharmaceutical Drugs Global Market Report 2018”:
1. Cardiovascular Drugs Global Market Report 2018
2. Biologics Global Market Report 2018
3. Contract Research Organizations Global Market Report 2018
4. Organ-on-Chip Global Market Report 2018

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here


Source: EIN Presswire

Opioids and Other Analgesics Are The Fastest-Growing Neurology Drugs

Central Nervous System Drugs Global Market Size 2021

Central Nervous System Drugs Global Market Size 2021

LONDON, GREATER LONDON, UK, June 21, 2018 /EINPresswire.com/ — The global market for analgesics, which includes opioids as well as anti-inflammatory drugs to relieve localized pain, is growing at over 8% year on year, a report from The Business Research Company shows. This compares with 6% for anaesthetics and 5% for anti-Parkinson drugs. Analgesics are drugs that relieve pain selectively without blocking the conduction of nerve impulses, noticeably changing sensory perception, or affecting consciousness. There are two types of analgesics – anti-inflammatory drugs that relieve modest pain by reducing local inflammatory responses and the opioids that act on the brain to reduce chronic pain.

In some parts of the world, such as the USA, experts suggest, there is an opioid crisis, resulting from the addictive properties of these drugs. It is claimed that more than two million Americans have become dependent on or abused prescription pain pills and street drugs. The number of opioid prescriptions dispensed by US doctors steadily increased from 112 million prescriptions in 1992 to a peak of 282 million in 2012, according to the market research firm IMS Health. Although the number of prescriptions dispensed has since declined, falling to 236 million in 2016, in that year there were still more than 42,249 overdose deaths that involved an opioid and Americans were the consumers of around 99% of all synthetic opioid drugs.
Analgesics are a segment of the wider market for drugs to treat neurological diseases, where growth is concentrated in smaller markets, particularly the BRICs (Brazil, Russia, India and China). The market for these drugs to treat diseases of the central nervous system (brain, spinal cord and nerves) in the four BRICs will all grow at 10% a year or above up to 2021. In the case of China and India this follows on from growth at this high level since 2010. Despite their large populations, however, the BRICs account for only a small proportion of the world's market for these drugs – 10% in 2017. In these emerging markets greater affordability of treatment resulting from growing GDP per capita and to some degree the arrival of low-priced generics help account for growth in the markets for these drugs.
In contrast with the rapid growth in the BRICs, the overall neurological drugs market in the USA, easily the world's largest, has been sluggish at 4%, though growing at a slightly faster 6% going forward. The Western European countries and Japan also have only moderate growth in the markets for these central nervous system drugs, so helping to hold back global growth to 5%. The global market will be worth $87 billion in 202, around 7.4% of the total for all pharma.
Drugs for neurological diseases are used to treat disorders such as epilepsy, Alzheimer’s disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinson's disease, neuroinfections, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.

The market for analgesic drugs is relatively concentrated, with the ten largest companies taking nearly 60% of the total. Biogen Inc. is market leader, followed by Johnson & Johnson, Pfizer, F. Hoffmann-La Roche and Novartis. Biogen’s Multiple Sclerosis Division, which manufactures central nervous system drugs, generated revenues of $8.3 billion for the financial year 2016, a 1.1% decrease from the previous year. Johnson & Johnson’s Total Neuroscience Division, that manufactures central nervous system drugs, also saw its revenues decrease, this time by 2.8% from the previous year. Smaller branded pharma rivals and generic drug manufacturers, however, benefitted from growing revenues from CNS drugs in 2016.

Where To Learn More
Read the Pharmaceutical Drugs Global Market Report 2018 from The Business Research Company for information on the following:
Markets Covered: Musculoskeletal disorder drugs, cardiovascular drugs, oncology drugs, anti-infective drugs, metabolic disorder drugs, central nervous system drugs, genito-urinary drugs, gastrointestinal drugs, hematology drugs, dermatology drugs, ophthalmology drugs, drugs for respiratory diseases.
Pharmaceutical Companies Covered: Novartis AG, Sanofi S.A., F. Hoffman-La Roche Ltd., Pfizer Inc. and Gilead Sciences Inc.
Regions: North America, Asia Pacific, Western Europe, South America, Eastern Europe, Middle East, Africa.
Countries: USA, China, Japan, Germany, Brazil, France, Italy, UK, Australia, India, Spain, Russia.
Time Series: Five years historic (2013-17) and forecast (2017-21).
Data: Ratios of market size and growth to related markets, population, GDP, Pharmaceutical Drugs Indicators Comparison.
Data Segmentations: Pharmaceutical drugs global market, global pharmaceutical drugs market by therapeutic area segments and sub segments; pharmaceutical drugs market by region and country and by therapeutic area segments; branded versus generic drugs markets by country; competitor drug sales and market shares by therapeutic area; global healthcare market historic and forecast size and growth; healthcare market regional and country size and growth; healthcare market competitive landscape.
Other Information: PESTEL analysis, drivers and restraints, customer information, pharmaceutical drugs market by region and country covering new drugs trials and approvals, regulations, government initiatives and competitive landscape; pharmaceutical drugs market trends and strategies.
Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes. Sources include primary as well as extensive secondary research.

Interested to know more? Here is a list of reports similar to “Pharmaceutical Drugs Global Market Report 2018”:
1.Central Nervous System Drugs Global Market Report 2018
2.Biologics Global Market Report 2018
3.Contract Research Organizations Global Market Report 2018
4.Organ-on-Chip Global Market Report 2018

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here


Source: EIN Presswire